| Identification | Back Directory | [Name]
BMY 21502 | [CAS]
123259-91-6 | [Synonyms]
BMY 21502
BMS-181168
BMY21502,BMY 21502
1-[[1-[2-(Trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolizinone
2-Pyrrolidinone, 1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]- | [Molecular Formula]
C15H19F3N4O | [MDL Number]
MFCD00880600 | [MOL File]
123259-91-6.mol | [Molecular Weight]
328.33 |
| Chemical Properties | Back Directory | [Melting point ]
118.5-120.5 °C | [Boiling point ]
421.9±45.0 °C(Predicted) | [density ]
1.305±0.06 g/cm3(Predicted) | [pka]
4.20±0.31(Predicted) |
| Hazard Information | Back Directory | [Uses]
BMY-21502 (BMS-181168) is a pyrrolidinone derivative with memory- and cognition-enhancing activities. BMS-181168 attenuates hypoxia-induced deterioration in brain function, as delta/theta decreases, alpha activity increases and the centroid of the combined delta/theta waves is accelerated[1]. | [References]
[1] Saletu B, et al. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Pharmacopsychiatry. 1994 Sep;27(5):189-97. DOI:10.1055/s-2007-1014303 |
|
|